|
Re: New Plan
The response by the tumor board to your FMI results is fascinating! Which mutations are suggestive of resistance to HER2 therapies, and why would an anti-HER2 TKI (e.g., Tykerb) be better equipped to overcome that resistance than a monoclonal antibody? I've never heard anything quite like this and am really curious.
Thank you for sharing! I also had an FMI test recently and am curious as to whether any of this would apply to me.
Best,
Lauren
|